I Wasn’t Finished! How to Work With an Interrupter

글 내용 전체보기

How Highlighting Your Soft Skills in the Job Interview Can Lead to a Job Offer

글 내용 전체보기

No Arrests in Murder of Apotex Founder and Wife Nearly One Year After

글 내용 전체보기

Updated: Mirum Pharmaceuticals Launches With Phase III-Ready Drug From Shire, $120 Million in Financing

글 내용 전체보기

Researchers Cure ALS in Laboratory Animals Using Gene Therapy

글 내용 전체보기

Will a New Biotech Cluster in Boston Challenge Kendall Square?

글 내용 전체보기

Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million

글 내용 전체보기

Bone Therapeutics Halts Phase III Trial for Futility, Stocks Plunge

글 내용 전체보기

Bio-what? The Future Is Here With Cemvita’s Biomimicry Tech Programs

글 내용 전체보기

BMS’ Empliciti Garners a New FDA Indication for Multiple Myeloma

글 내용 전체보기

Jazz’s Vyxeos rollout hit a wall in Q3. What’s the holdup?

글 내용 전체보기

New Lundbeck CEO Dunsire, armed with plenty of cash, embarks on strategic review

글 내용 전체보기

Recro Pharma expands CDMO business in Georgia

글 내용 전체보기

Mylan overhaul of West Virginia plant has a ways to go

글 내용 전체보기

Think a Democrat-led House will only focus on drug pricing proposals? Sorry, pharma. Think again

글 내용 전체보기

https://www.fiercebiotech.com/biotech/mirum-scoops-120m-to-take-ex-shire-drug-into-phase-3

글 내용 전체보기

https://www.fiercebiotech.com/biotech/sitc-merck-highlights-new-lag-3-and-tigit-data

글 내용 전체보기

SITC18: Merck highlights new LAG-3 and TIGIT data

글 내용 전체보기

Bye bye biosimilars: Big Pharma’s imminent exit in sight, says expert

글 내용 전체보기

Catalent pumping $200m into biomanufacturing expansions

글 내용 전체보기

Clues to making drugs for “undruggable” targets

글 내용 전체보기